Streetwise Articles



Co. Uses RNA Editing as Treatment for Rare Disease
Source: Andrew Fein  (10/3/22)
The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report. More >


Interim Results From Phase 2b Trial Are 'Encouraging'
Source: Dr. Elemer Piros  (9/30/22)
Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report. More >


Biopharma Co. Awarded FDA Clearance for Advanced Solid Tumors Trial
Source: Streetwise Reports  (9/30/22)
Shares of oncology-focused biopharmaceutical company Immuneering Corp. traded 9% higher after the firm reported it received U.S. FDA clearance for its IND Application for a Phase 1/2a clinical trial of IMM-1-104 for use in treatment of advanced solid tumors with RAS mutations. The company expects to enroll the first patient in the study in Q4/22. More >


Pharma Co. Meets Primary Endpoint in Phase 3 Alzheimer's Trial
Source: Streetwise Reports  (9/29/22)
Shares of Eisai Co. Ltd. traded 58% higher yesterday after the company reported topline data from its global Phase 3 clinical study demonstrating that its lecanemab significantly met the primary and key secondary endpoints in reducing mild cognitive impairment due to Alzheimer's disease. More >


Biopharma Asks for Emergent Use in US of New COVID Drug
Source: Edward White  (9/29/22)
The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report. More >


Oncology Co.'s Shares Erupt on Signing Global License Deal
Source: Streetwise Reports  (9/27/22)
Shares of clinical-stage immuno-oncology company LAVA Therapeutics NV traded nearly 100% higher yesterday after the firm reported that it has entered into a global licensing agreement with Seagen Inc. to advance its LAVA-1223, a preclinical gamma delta bispecific T cell engager designed for use in the treatment of EGFR-expressing solid tumors. More >


Opportunity for Investors Found in Psychedelics Space
Source: Patrick R. Trucchio  (9/27/22)
Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report. More >


US Biotech Firm Keeps Growing Revenue
Source: Scott Henry  (9/26/22)
Revenue last quarter was strong, and management expects to increase revenue 20% this fiscal year, noted a ROTH Capital Partners report. More >


Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating
Source: Dr. Joseph Pantginis  (9/23/22)
To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report. More >


Analyst Says Buy Before Biotech Co.'s Clinical Trials
Source: Dr. David Nierengarten  (9/23/22)
Argenx SE has "several upcoming catalysts," noted a Wedbush report. More >


Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World
Source: Streetwise Reports  (9/21/22)
The pandemic changed the way many people get their basic healthcare, giving a big opening to telemedicine companies like Reliq Health Technologies Inc. More >


FDA Approves Hearing Loss Drug for Child Chemo Patients
Source: Streetwise Reports  (9/21/22)
Shares of Fennec Pharmaceuticals Inc. traded 14% higher after the company reported it received approval from the U.S. FDA for its PEDMARK® (sodium thiosulfate injection) for use in reducing the risk of ototoxicity in pediatric patients who are undergoing or completed chemotherapy for non-metastatic solid tumors. More >


Dermatology Co.'s Target Price Much Higher Than Current
Source: Dr. Jonathan Aschoff  (9/20/22)
The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report. More >


Important Catalyst Expected Soon for Cancer Drug Co.
Source: Dr. David Nierengarten  (9/20/22)
The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report. More >


Biopharma Co.'s Shares Rise on Phase 3 Migraine Trial Data
Source: Streetwise Reports  (9/20/22)
Satsuma Pharmaceuticals Inc. shares traded 12% higher to a new 52-week high after the company reported positive results from its Phase 3 long-term study of STS101 for use in acute treatment of migraine attacks. The company expects to receive further efficacy data from its Phase 3 SUMMIT trial in Q4/22, which it believes will support submission of an NDA with the U.S. FDA in Q1/23. More >


Second Trial of New Eczema Drug To Commence in Q4/22
Source: Dr. Yi Chen  (9/17/22)
The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report. More >


FDA Grants Approval for Drug Improving Kidney Function
Source: Streetwise Reports  (9/16/22)
Shares of Mallinckrodt Plc. traded 28% higher yesterday after the company reported that the U.S. FDA has issued approval for its Terlivaz® (terlipressin) for injection for use in treating hepatorenal syndrome, a serious and life-threatening condition that is accompanied by rapid reduction in kidney function. More >


Price Target on US Biopharma Co. Boosted by $15
Source: Julian Harrison  (9/15/22)
The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report. More >


New Drug Shown To Help Patients With Desmoid Tumors
Source: Dr. David Nierengarten  (9/15/22)
This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report. More >


Several Trials of Co.'s Fluid Pump To Read Out This Year
Source: Dr. Yi Chen  (9/14/22)
Positive topline data could boost the share price of this Swiss medical device firm, noted an H.C. Wainwright & Co. report. More >


Co. Advancing Drug Class With Broad Potential
Source: Dr. Thomas Shrader   (9/13/22)
This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report. More >


Biotech Co.'s Target Six Times Current Price
Source: Francois Brisebois  (9/13/22)
One Phase 2 clinical trial showing LSD reduced symptoms of anxiety bodes well for other studies of LSD in this indication. In light of this, Oppenheimer & Co. gave this biotech company a target price that is over six times its current share price. More >


Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'
Source: Clive Maund  (9/13/22)
Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive. More >


Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet
Source: Streetwise Reports  (9/12/22)
One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run. More >


Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise
Source: Dr. Jonathan Aschoff  (9/12/22)
Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report. More >


Showing Results: 1 to 25 of 2240 Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts